Published in Clin Cancer Res on April 15, 2016
A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol (2016) 0.80
Exosomes carrying immunoinhibitory proteins and their role in cancer. Clin Exp Immunol (2017) 0.78
Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Onco Targets Ther (2016) 0.75
Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Front Oncol (2016) 0.75
Advancing Immune and Cell-Based Therapies Through Imaging. Mol Imaging Biol (2017) 0.75
FCGR Polymorphisms Influence Response to IL-2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res (2016) 0.75
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Front Pharmacol (2016) 0.75
Tracking dendritic cell migration into lymph nodes by using a novel PET probe (18)F-tetrafluoroborate for sodium/iodide symporter. EJNMMI Res (2017) 0.75
Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
The future of immune checkpoint therapy. Science (2015) 5.59
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Neoantigens in cancer immunotherapy. Science (2015) 5.16
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol (2015) 3.57
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med (2014) 2.96
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol (2015) 2.52
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 2.40
Regulatory T cells in cancer immunotherapy. Curr Opin Immunol (2014) 2.32
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity (2014) 2.28
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med (2015) 2.20
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res (2013) 2.19
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst (1979) 1.48
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res (2013) 1.47
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med (2013) 1.47
Balancing natural killer cell activation through paired receptors. Nat Rev Immunol (2015) 1.44
"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer (2010) 1.43
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology (2014) 1.39
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer (2013) 1.34
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer (2006) 1.32
Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol (2014) 1.29
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol (2012) 1.23
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood (2001) 1.21
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol (2012) 1.21
Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 1.19
Modulation of GITR for cancer immunotherapy. Curr Opin Immunol (2012) 1.17
Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol (2015) 1.17
Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res (2014) 1.17
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res (2012) 1.15
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle (2007) 1.15
FDA Approval: Blinatumomab. Clin Cancer Res (2015) 1.12
Reactive oxygen species in redox cancer therapy. Cancer Lett (2015) 1.11
Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol (2015) 1.11
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res (2014) 1.09
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol (2015) 1.06
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02